Aug 18, 2017 by Brian Feroldi, Rich Duprey, and Demitri Kalogeropoulos3 Stocks That Are Absurdly Cheap Right NowCarrols Restaurant Group, GameStop, and TEVA Pharmaceuticals are all trading at a discount, but are any of them worth buying?
Aug 17, 2017 by Brian Feroldi, Sean Williams, and Daniel Miller3 Stocks That Could Soar More Than McDonald'sLooking for a few stocks that could go on a McDonald's-like run? Here's why you should check out Activision Blizzard, American Eagle Outfitters, and Quintiles IMS Holdings.
Aug 16, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhD3 Dividend Healthcare StocksOn the hunt for income? Here's why our team of healthcare experts thinks you should check out AbbVie, Medtronic, and ResMed.
Aug 16, 2017 by Brian Feroldi, Rich Duprey, and Demitri Kalogeropoulos3 Stocks That Could Soar More Than PricelineLooking for a few stocks that hold massive upside potential? JD.com, Take-Two Interactive, and Novocure could be for you.
Aug 11, 2017 by Brian Feroldi, Sean Williams, and Daniel Miller3 Billionaire Stocks for RetireesWant a few stock ideas that are handpicked by some of the most successful investors of our time? Here's why you should check out Johnson & Johnson, Advance Auto Parts, and Kroger.
Aug 10, 2017 by Brian Feroldi, Rich Duprey, and Demitri Kalogeropoulos3 Value Stocks for Wise InvestorsLooking for value in today's pricey market? Here's why our team thinks you should check out Amplify Snack Brands, Target, and AbbVie.
Aug 10, 2017 by Brian FeroldiHere's Why Synergy Pharmaceuticals Inc. Is Falling TodayShares tumble after the company reports a higher-than-expected loss in the second quarter.
Aug 10, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhD3 High-Yield Healthcare StocksLooking for income from the healthcare sector? Here's why you should check out GlaxoSmithKline, Pfizer, and CVS Health.
Aug 9, 2017 by Brian FeroldiHere's Why Acadia Pharmaceuticals Inc. Is Soaring TodayShares popped after the company reported better-than-expected second quarter results and issued bullish full-year guidance.
Aug 9, 2017 by Brian FeroldiHere's Why NantKwest Inc. Tumbled 21.1% in JulyNews that a law firm is investigating the company's board of directors for possible breaches of their fiduciary duty causes shares to tank.
Aug 9, 2017 by Brian FeroldiIs This Why bluebird bio Dipped 10.5% in July?It was a quiet month for the clinical-stage biotech, but that didn't stop its share price from dropping by double digits.
Aug 8, 2017 by Brian FeroldiSynergy Pharmaceuticals Inc. Tanked 14.2% in July -- but Why?It was a quiet month for the commercial-stage biopharma, but that didn't stop its shares from tumbling.
Aug 8, 2017 by Brian FeroldiWhy Evolent Health, Inc. Is Plunging TodayShares tumble after the company reports second-quarter earnings results and announces yet another common stock offering.
Aug 8, 2017 by Brian FeroldiHere's Why Inovio Pharmaceuticals, Inc. Sank 30.8% in JulyShares slumped after the company announced disappointing pricing results from a common stock offering.
Aug 7, 2017 by Brian FeroldiHere's Why Array BioPharma Inc. Fell 13.7% in JulyDespite sharing upbeat news, shares of the clinical-stage biotech fell by double-digits.
Aug 7, 2017 by Brian FeroldiWhy Minerva Neurosciences Inc. Fell 31.1% in JulyThese two news items were the primary reasons that Minerva's stock shed nearly a third of its value last month.
Aug 7, 2017 by Brian FeroldiWhy NxStage Medical, Inc. Is Skyrocketing TodayNews that the company has accepted a buyout offer sends shares higher.
Aug 7, 2017 by Brian FeroldiHere's Why Impax Laboratories Inc Jumped 18% In JulyShareholders can thank a series of positive developments for the double-digit gains.
Aug 4, 2017 by Brian FeroldiInfinera Tumbles on Downbeat Guidance, but the Bottom Might Finally Be in SightWeak guidance causes Infinera's stock to plunge, but management believes that the long-term future is looking up.
Aug 4, 2017 by Brian FeroldiQuintiles IMS Holdings Continues to ExecuteThere were no big surprises from the life sciences service provider in its second-quarter earnings report.
